Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3910291
Max Phase: Preclinical
Molecular Formula: C23H16N6
Molecular Weight: 376.42
Molecule Type: Small molecule
Associated Items:
ID: ALA3910291
Max Phase: Preclinical
Molecular Formula: C23H16N6
Molecular Weight: 376.42
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cccc(-c2cc3c(cn2)ncc2ncn(-c4ccc5nc[nH]c5c4)c23)c1
Standard InChI: InChI=1S/C23H16N6/c1-14-3-2-4-15(7-14)19-9-17-21(10-24-19)25-11-22-23(17)29(13-28-22)16-5-6-18-20(8-16)27-12-26-18/h2-13H,1H3,(H,26,27)
Standard InChI Key: RMBNGICVQYNHSG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 376.42 | Molecular Weight (Monoisotopic): 376.1436 | AlogP: 4.82 | #Rotatable Bonds: 2 |
Polar Surface Area: 72.28 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.22 | CX Basic pKa: 6.31 | CX LogP: 3.91 | CX LogD: 3.88 |
Aromatic Rings: 6 | Heavy Atoms: 29 | QED Weighted: 0.47 | Np Likeness Score: -1.25 |
1. Glatthar R, Stojanovic A, Troxler T, Mattes H, Möbitz H, Beerli R, Blanz J, Gassmann E, Drückes P, Fendrich G, Gutmann S, Martiny-Baron G, Spence F, Hornfeld J, Peel JE, Sparrer H.. (2016) Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors., 59 (16): [PMID:27502541] [10.1021/acs.jmedchem.6b00598] |
Source(1):